A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy

Ayati, Adileh; Moghimi, Setareh; Salarinejad, Somayeh; Safavi, Maliheh; Pouramiri, Behjat; Foroumadi, Alireza

doi:10.1016/j.bioorg.2020.103811

Cited by 218 publications

(164 citation statements)

References 119 publications

Supporting

Mentioning

163

Contrasting

Order By: Relevance

“…The epidermal growth factor receptor (EGFR, also known as ErbB1 or HER-1) belongs to the receptor tyrosine kinase (RTK) superfamily, which consists of other three members, ErbB2/Neu/HER-2, ErbB3/HER-3 and ErbB4/HER-4 [1,2]. EGFR was the first member of the family to be discovered [3] and, up to now, seven ligands are known to activate this receptor [4].…”

Section: Introductionmentioning

confidence: 99%

“…As a result of the activation of the intrinsic kinase domain following ligand binding, specific tyrosine residues in the cytoplasmic tail are phosphorylated, becoming binding sites for adaptor proteins with Src-homology 2 domains (SH2) and activating downstream signaling pathways. Among these, the Ras-Raf-MEK-ERK1/2, STAT3 and STAT5 pathways and the PI3K-Akt-mTOR cascade are the main pathways activated by ligand binding to Erb receptors and they are fundamental in the regulation of cellular proliferation, differentiation and survival [ 1 , 2 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of EGFR in the Nervous System

Romanò

Bucci

2020

Cells

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is the first discovered member of the receptor tyrosine kinase superfamily and plays a fundamental role during embryogenesis and in adult tissues, being involved in growth, differentiation, maintenance and repair of various tissues and organs. The role of EGFR in the regulation of tissue development and homeostasis has been thoroughly investigated and it has also been demonstrated that EGFR is a driver of tumorigenesis. In the nervous system, other growth factors, and thus other receptors, are important for growth, differentiation and repair of the tissue, namely neurotrophins and neurotrophins receptors. For this reason, for a long time, the role of EGFR in the nervous system has been underestimated and poorly investigated. However, EGFR is expressed both in the central and peripheral nervous systems and it has been demonstrated to have specific important neurotrophic functions, in particular in the central nervous system. This review discusses the role of EGFR in regulating differentiation and functions of neurons and neuroglia. Furthermore, its involvement in regeneration after injury and in the onset of neurodegenerative diseases is examined.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of EGFR in the Nervous System

Romanò

Bucci

2020

Cells

View full text Add to dashboard Cite

show abstract

“…Kim et al [ 16 ] reported that hydrophobic quantum dots (QDs) [ 17 ] were effectively incorporated into lipid bilayers, and then therapeutic short-interfering RNAs (siRNAs) [ 18 ] were complexed with QD-lipid nanocarriers (QLs). Anti-epidermal growth factor receptor [ 19 ] (EGFR) aptamer-lipid conjugates were inserted into the QLs for triple-negative breast cancer (TNBC) targeting. These TNBC-targeted constructs, aptamo-QLs, were directly compared to anti-EGFR antibody-coupled immuno-QLs.…”

Section: Targeted Deliverymentioning

confidence: 99%

Recent advances in aptamer applications for analytical biochemistry

Zon

2022

Analytical Biochemistry

View full text Add to dashboard Cite

Aptamers are typically defined as relatively short (20–60 nucleotides) single-stranded DNA or RNA molecules that bind with high affinity and specificity to various types of targets. Aptamers are frequently referred to as “synthetic antibodies” but are easier to obtain, less expensive to produce, and in several ways more versatile than antibodies. The beginnings of aptamers date back to 1990, and since then there has been a continual increase in aptamer publications. The intent of the present account was to focus on recent original research publications, i.e., those appearing in 2019 through April 2020, when this account was written. A Google Scholar search of this recent literature was performed for relevance-ranking of articles. New methods for selection of aptamers were not included. Nine categories of applications were organized and representative examples of each are given. Finally, an outlook is offered focusing on “faster, better, cheaper” application performance factors as key drivers for future innovations in aptamer applications.

show abstract

“… 3 Because most cancers have progressed to the middle or late stages when diagnosed, molecular targeted drug therapy and chemotherapy are the main treatment options. 4 The most common therapeutic drugs include cisplatin, sorafenib, oxaliplatin, 5-fluorouracil, and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). 5 However, long-term therapies usually lead to acquired drug resistance and poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications

Song

Liu

Dong

et al. 2020

Sig Transduct Target Ther

View full text Add to dashboard Cite

Drug resistance is a major hurdle in cancer treatment and a key cause of poor prognosis. Epitranscriptomics and epiproteomics are crucial in cell proliferation, migration, invasion, and epithelial–mesenchymal transition. In recent years, epitranscriptomic and epiproteomic modification has been investigated on their roles in overcoming drug resistance. In this review article, we summarized the recent progress in overcoming cancer drug resistance in three novel aspects: (i) mRNA modification, which includes alternative splicing, A-to-I modification and mRNA methylation; (ii) noncoding RNAs modification, which involves miRNAs, lncRNAs, and circRNAs; and (iii) posttranslational modification on molecules encompasses drug inactivation/efflux, drug target modifications, DNA damage repair, cell death resistance, EMT, and metastasis. In addition, we discussed the therapeutic implications of targeting some classical chemotherapeutic drugs such as cisplatin, 5-fluorouridine, and gefitinib via these modifications. Taken together, this review highlights the importance of epitranscriptomic and epiproteomic modification in cancer drug resistance and provides new insights on potential therapeutic targets to reverse cancer drug resistance.

show abstract

A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy

Cited by 218 publications

References 119 publications

Role of EGFR in the Nervous System

Role of EGFR in the Nervous System

Recent advances in aptamer applications for analytical biochemistry

Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications

Contact Info

Product

Resources

About